Analyst firms · Leerink Partners · NPCE

Leerink Partners NPCE price target and rating history

Neuropace Inc. (NPCE) · Health Care

Leerink Partners rates Neuropace Inc. (NPCE) Market Perform with a $7 price target, as of its latest action on Nov 13, 2026. It has published 3 rating actions on NPCE since March 2022, including 0 upgrades and 1 downgrade. Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50. Leerink Partners's $7 is 48% below that.

Current rating
Market Perform
Price target
$7
Median target, all firms
$13.50
Actions on NPCE
3

Leerink Partners price target on NPCE

$22$15$72023202420252026
Leerink Partners price target on NPCE, each point a stated target, March 2022 to November 2026.

Every Leerink Partners rating on NPCE

How other firms rate NPCE

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoEqual Weight$9Nov 13, 2026
Leerink PartnersMarket Perform$7Nov 13, 2026
KeyBanc Capital MarketsOverweight$18Sep 18, 2026
MizuhoOutperform$22Jul 23, 2026

Questions about Leerink Partners and NPCE

What is Leerink Partners's price target for NPCE?
Leerink Partners's latest stated price target for Neuropace Inc. (NPCE) is $7, from its action on Nov 13, 2026.
What is Leerink Partners's rating on NPCE?
Leerink Partners rates NPCE Market Perform, a neutral rating, as of Nov 13, 2026.
When did Leerink Partners last change its view on NPCE?
On Nov 13, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $7.
How does Leerink Partners's NPCE target compare with other analysts?
Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50. Leerink Partners's $7 is 48% below that.

More NPCE rating histories

All Leerink Partners ratingsNPCE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.